Patents Examined by Tamthom N. Truong
  • Patent number: 7300937
    Abstract: New derivatives of cyanoaryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines (I), where R1 represents an OR3 radical, where R3 represents a radical derived from a saturated hydrocarbon, with a linear or branched chain of 1 to 4 carbon atoms, and R2 represents a phenyl radical substituted at least by one cyan radical (—C?N), or a radical of a heteroaromatic ring of 5 or 6 members substituted at least by one cyan radical (—C?N); and their physiologically acceptable salts, are useful for application in human and/or veterinary therapeutics as sedatives, anticonvulsants, hypnotics and general anaesthetics
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: November 27, 2007
    Assignee: Laboratorios del Dr. Esteve, S.A.
    Inventors: Jordi Corbera-Arjona, David Vano-Domenech, Maria Neus Mesquida-Estevez, Jordi Frigola-Constansa
  • Patent number: 7294629
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: November 13, 2007
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Yasunori Kitano, Eiji Kawahara, Tsuyoshi Suzuki, Daisuke Abe, Masahiro Nakajou, Naoko Ueda
  • Patent number: 7294634
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: November 13, 2007
    Assignee: Cytokinetics, Inc.
    Inventors: Jeffrey T. Finer, Gustave Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
  • Patent number: 7285557
    Abstract: A compound of formula (Ia) comprising a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: October 23, 2007
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Andrew J Carpenter, Joel P Cooper, Anthony L Handlon, Donald L Hertzog, Clifton E Hyman, Yu C Guo, Jason D Speake, David Richard Witty
  • Patent number: 7271260
    Abstract: The present invention relates to 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and a method of preparing the same. The present invention further relates to a composition comprising the same. The composition comprising the 3,4-dihydroquinazoline derivatives of the present invention can be effectively used for preventing and treating angina pectoris, high blood pressure, myocardial disease, pain and epilepsy by blocking the T-type calcium channel.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: September 18, 2007
    Assignee: Korea Institute of Science and Technology
    Inventors: Yong Sup Lee, Jae Yeol Lee, Hyewhon Rhim
  • Patent number: 7268230
    Abstract: The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as defined herein; (ii) Q15W3 wherein Q15 and W3 are as defined herein, (iii) Q21W4C1-5alkylX1— wherein Q21, W4 and X1 are as defined herein, (iv) Q28C1-5alkylX1—, Q28C2-5alkenylX1— or Q28C2-5alkynylX1— wherein Q28 and X1 are as defined herein and (v) Q29C1-5alkylX1—, Q29C2-5alkenylX1— or Q29C2-5alkynylX1— wherein Q29 and X1 are as defined herein; R2 can also be 6,7-methylenedioxy or 6,7-ethylenedioxy; and salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm?blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: September 11, 2007
    Assignee: AstraZeneca AB
    Inventor: Laurent Francois Andre Hennequin
  • Patent number: 7268142
    Abstract: The invention pertains to substituted quinazoline and isoquinoline compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE-10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: September 11, 2007
    Assignee: Pfizer Inc.
    Inventors: Martin Patrick Allen, Thomas Allen Chappie, John Michael Humphrey, Spiros Liras, William Michael Whalen
  • Patent number: 7262201
    Abstract: The invention relates to the use of compounds of the formula I: wherein: ring C is a 5-6 membered heterocyclic moiety; Z is —O—, —S—, or —CH2—; R1 is hydrogen, C1-4alkyl, C1-4alkoxymethyl, di(C1-4)alkoxy)methyl, C1-4alkanoyl, trifluoromethyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, carboxy, C3-7cycloalkyl, C3-7-cycloalkylC1-3alkyl, or an optionally substituted group selected from phenyl, benzyl, phenylC2-4alkyl and a 5-6 membered heterocyclic group; n is an integer from 0 to 5; m is an integer from 0 to 3; R2 represents hydrogen, hydroxy, halgeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein X1 represents a direct bond, —CH2—, or a heteroatom linker group and R5 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl an
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: August 28, 2007
    Assignee: AstraZeneca AB
    Inventors: Laurent F A Hennequin, Georges Pasquet
  • Patent number: 7259155
    Abstract: The present invention provides a phosphonic acid diester compound represented by General Formula wherein R1, R2, R3 and R4 are the same or different, and represent hydrogen, halogen, lower alkyl or lower alkoxy; R5 is phenyl having on the phenyl ring 1–3 substituents selected from the group consisting of lower alkyl, halogen-substituted lower alkyl, lower alkoxy, halogen-substituted lower alkoxy, phenoxy, benzyloxy, hydroxyl, halogen, nitro, lower alkylthio, di(lower alkyl)amino, lower alkanolyamino, pyrrolidinyl and phenyl, or the like, provided that R5 is not mono(lower alkoxy)pheny; and R6 is lower alkyl; and an ACAT-1 inhibitor containing the compound as an active ingredient.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: August 21, 2007
    Assignee: Otsuka Pharmaceutical Factory, Inc.
    Inventors: Yasuhiro Sakai, Kazuyoshi Miyata, Takahiro Tomoyasu, Akiyoshi Kuroda, Yasuhide Inoue, Akifumi Hagi, Shinya Miki, Norihiro Yoshinaga, Masako Doi, Yoshihiko Tsuda, Seiichirou Kanou
  • Patent number: 7244746
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: July 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiaojun Han, Gene M. Dubowchik, John E. Macor
  • Patent number: 7244738
    Abstract: Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R?, R5 and R10 are as defined herein.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: July 17, 2007
    Assignee: Roche Palo Alto LLC
    Inventors: Terrence Joseph Connolly, Paul Francis Keitz, Eun Kyung Lee, Jim Li, Francisco Javier Lopez-Tapia, Patrick Finbar McGarry, Chris Richard Melville, Dov Nitzan, Counde O'Yang, Fernando Padilla, Klaus Kurt Weinhardt
  • Patent number: 7241777
    Abstract: This invention comprises the novel compounds of formula (I) wherein r, t, Y1, Y2, R1, R2, R3, R5, R6and R7 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: July 10, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Patrick René Angibaud, Marc Gaston Venet, Christophe Meyer, Henry Joseph Breslin
  • Patent number: 7241767
    Abstract: Compounds of Formula I including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof, are disclosed which are useful as invertebrate pest control agents, (I) wherein A, B, J, K, L and R3 are as defined in the disclosure. Also disclosed are compositions for controlling an invertebrate pest comprising a biologically effective amount of a compound of Formula I an N-oxide thereof or a suitable salt thereof and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula I, its N-oxide or a suitable salt of the compound (e.g.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: July 10, 2007
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: David Alan Clark, George Philip Lahm
  • Patent number: 7238679
    Abstract: Compounds of the following formula are disclosed: wherein RB is a substituted or unsubstituted aryl or heteroaryl moiety; at least one of RU and RL is a phosphorus-containing moiety, J, and the other of RU and RL is independently chosen from H; halogen; —CN; —NO2; -J; —SO2R; —SO2NRR?; or —ZRJ, wherein each occurrence of Z is independently —O—, —S— or —NR— and each occurrence of RJ is independently —R, —COR, —COOR or —CONRR?.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: July 3, 2007
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Terence P. Keenan, William C. Shakespeare
  • Patent number: 7238699
    Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: July 3, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Bireshwar Dasgupta, Gene M. Dubowchik, John E. Macor
  • Patent number: 7235575
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: June 26, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Celia Dominguez, John M. Fevig, Qi Han, Renhua Li, Donald J P Pinto, James R. Pruitt, Mimi L. Quan
  • Patent number: 7235550
    Abstract: The invention relates to compounds of formula (I): wherein: G1 represents an alkylene chain as defined in the description, A represents R2 and R3 represent hydrogen, alkyl, alkoxy or hydroxy or together form oxo, R4 and R5 represent hydrogen, R1 is as defined in the description, and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: June 26, 2007
    Assignee: Les Laboratoires Servier
    Inventors: Gérald Guillaumet, Marie-Claude Viaud, Hervé Van de Poel, Philippe Delagrange, Caroline Bennejean, Pierre Renard
  • Patent number: 7230000
    Abstract: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 12, 2007
    Assignee: Cytokinetics, Incorporated
    Inventors: Jeffrey T. Finer, Gustave Bergnes, Whitney W. Smith, John C. Chabala, Bainian Feng
  • Patent number: 7226915
    Abstract: This invention relates to diaminopyrroloquinazoline compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: June 5, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Kshitij Chhabilbhai Thakkar
  • Patent number: 7226927
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: wherein A, Ar1, Ar2, R1 and R3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: June 5, 2007
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A Drewe, P. Sanjeeva Reddy, Bao Nguyen, Azra Pervin